US 12,220,483 B2
Liposome compositions comprising weak acid drugs and uses thereof
Pei Kan, Taipei (TW); Yi Fong Lin, New Taipei (TW); and Ko Chieh Chen, Taipei (TW)
Assigned to Pharmosa Biopharm Inc., Taipei (TW)
Filed by Pharmosa Biopharm Inc., Taipei (TW)
Filed on Mar. 18, 2024, as Appl. No. 18/608,182.
Application 18/608,182 is a continuation of application No. 16/043,126, filed on Jul. 23, 2018, granted, now 11,964,050.
Claims priority of provisional application 62/595,207, filed on Dec. 6, 2017.
Claims priority of provisional application 62/536,034, filed on Jul. 24, 2017.
Prior Publication US 2024/0216277 A1, Jul. 4, 2024
Int. Cl. A61K 9/127 (2006.01); A61K 31/5585 (2006.01); A61K 47/02 (2006.01); A61P 11/06 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 9/1271 (2013.01); A61K 9/1278 (2013.01); A61K 31/5585 (2013.01); A61K 47/02 (2013.01); A61P 11/06 (2018.01)] 20 Claims
 
1. A method for treating a respiratory disease, comprising the steps of administering a pharmaceutical composition comprising liposomes, said liposomes comprising:
(a) a lipid bilayer, comprising vesicle-forming lipid; and
(b) an internal aqueous medium inside the lipid bilayer, comprising a bicarbonate salt and a weak acid drug with a pKa between about 1 to about 6,
wherein the liposomes are suspended in an external medium, the concentration of the bicarbonate salt is about 50 mM to less than about 1000 mM, the pH of the external medium is above the pKa of the weak acid drug and the vesicle-forming lipid comprises a mixture of a first phospholipid and a second phospholipid or a mixture of a first phospholipid and a charged lipid, and
wherein the encapsulation efficiency of the weak acid drug is at least about 50%.